InMed Pharmaceuticals Inc.
INM
We are a pharmaceutical company developing a pipeline of proprietary small molecule drug candidates that are preferential signaling ligands of the endogenous CB1 and CB2 receptors as well as other receptor targets linked to human disease. CB1 and CB2 receptors are each part of the endocannabinoid system that is found throughout the human body and is responsible for many homeostatic functions.
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue
N/A
Net Income (TTM)
-$13M
▼ -53.9% YoY
Op. Margin
–
ROIC
–
Cash Flow & Balance Sheet
FCF (TTM)
-$8M
▼ -6.7% YoY
Op. Cash Flow (TTM)
-$8M
▼ -6.7% YoY
Net Debt
-$1M
Net Cash Position
Cash & Equiv.
$1M
3Y CAGR: +65.5%
Continue Research
Peers
Pharmaceutical Preparations · Pick stocks to compare with INM
InMed Pharmaceuticals (INM) in three numbers
Questions about InMed Pharmaceuticals
Is InMed Pharmaceuticals a high-quality business?
InMed Pharmaceuticals scores 40 out of 100 on Intrinsiqq's quality score, which makes it a mixed business on these measures. The score blends 6 checks computed from SEC filings. Its best check is revenue growth at 65.5%, and its weakest is return on capital at -42.4%. The Quality tab shows every check against its target.
Does InMed Pharmaceuticals (INM) pay a dividend?
No. InMed Pharmaceuticals (INM) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold. Nor has its share count fallen meaningfully over the last twelve months, so cash is kept in the business. The Dividends tab shows its cash returns.
Source: 10-Q filed 30 Oct 2026 (period ending 30 Sept 2026), SEC. Price: last close 5 Nov 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.
Spot a number that looks wrong? Check it in INM's SEC filings or
Download this analysis as a PDF (Pro)
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing INM
A free account gives you 10 stocks a day, a watchlist and price alerts.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.